At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 263 enrolled
Drug / intervention
Telaprevir +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment
In Brief
A Phase 2 clinical trial evaluating Telaprevir, Ribavirin, and 2 other interventions for Chronic Hepatitis C. Completed, enrolled 263 participants across 37 sites in 2 countries.
Detailed Summary
Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJun 2006
Primary CompletionFeb 2008
TodayJul 2026
First PostedJun 13, 2006
Enrollment StartJun 1, 2006
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 20.1 years ago
Interventions
Telaprevirdrug
tablet
Ribavirindrug
tablet
Pegylated Interferon Alfa 2adrug
Solution for injection
Placeboother
matching placebo tablet